Protocol Ledger

NCT04889040 · Phase III · TERMINATED

Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19

Interventional Phase III clinical trial protocol NCT04889040 sponsored by Roche / Genentech in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-04-28 Enrollment: 216 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04889040
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)216 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04889040
Protocol FieldVerified Registry Value
NCT IdentifierNCT04889040
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment216 participants (ACTUAL)
Registered Start Date2021-04-28
WhyStopped ClassificationUnspecified

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI